Agenda
ESMO Virtual Data Briefing
14:30 - 15:30 CET
08:30 - 09:30 ET
Tuesday, September 22, 2020
|
SESSION TITLE |
SPEAKERS |
|---|---|
|
Opening and Welcome |
Robert LaCaze, Member of the Executive Committee of Bayer’s Pharmaceutical Division and Head of the Oncology Strategic Business Unit |
|
Bayer’s Commitment to Advancing Patient Care Through Research and Innovation |
Dr. Scott Z. Fields, SVP and Head of Oncology Development at Bayer's Pharmaceuticals Division |
|
Integrated Larotrectinib Analysis: Contextualizing Expanded Data for Patients with TRK Fusion Cancer |
Professor Ray McDermott, MD, PhD, St. Vincent University Hospital and Tallaght Hospital, Ireland |
|
Pediatric Focus: Understanding Larotrectinib for the Treatment of TRK Fusion Cancer in Children and Adolescents |
Theodore W. Laetsch, MD, Children’s hospital of Philadelphia, Pennsylvania, USA |
|
Interactive Media Q&A |
All panelists |